Modern nuclear medicine evaluation of neuroblastoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 4, 2010, Pages 389-400

  Pfluger T ^a   Schmid, I ^a   Coppenrath, E ^a   Weiss, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

3 Iodobenzylguanidine radionuclide imaging; Child; Neuroblastoma; Positron emission tomography

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; 3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; HYDROXYEPHEDRINE C 11; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; BONE SCINTISCANNING; BRAIN SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DOSIMETRY; DRUG HALF LIFE; DRUG UPTAKE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; GANGLIONEUROMA; HUMAN; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; ORBIT METASTASIS; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; RHABDOMYOSARCOMA; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BIOPSY;

3-IODOBENZYLGUANIDINE; BONE NEOPLASMS; CHILD; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; NEUROBLASTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78650665001     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Belgaumi AF, Kauffman WM, Jenkins JJ, Cordoba J, Bowman LC, Santana VM et al. Blindness in children with neuroblastoma. Cancer 1997;80:1997-2004.
2. Kropp J, Hofmann M, Bihl H. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor? Anticancer Res 1997;17(3B):1583-8.
3. Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008;44:1552-8.
4. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:403-18.
5. Custodio CM, Semelka RC, Balci NC, Mitchell KM, Freeman JA. Adrenal neuroblastoma in an adult with tumor thrombus in the inferior vena cava. J Magn Reson Imaging 1999;9:621-3.
6. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 2008;35(Suppl 1):S35-48.
7. Boubaker A, Bischof Delaloye A. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. QJ Nucl Med 2003;47:31-40.
8. Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. QJ Nucl Med Mol Imaging 2008;52:388-402.
9. Hugosson C, Nyman R, Jorulf H, McDonald P, Rifai A, Kofide A et al. Imaging of abdominal neuroblastoma in children. Acta Radiol 1999;40:534-42.
10. Sofka CM, Semelka RC, Kelekis NL, Worawattanakul S, Chung CJ, Gold S et al. Magnetic resonance imaging of neuroblastoma using current techniques. Magn Reson Imaging 1999;17:193-8.
11. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villabianca JG et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009;27:5343-9.
12. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 1231-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009;50:1237-43.
13. Mc Dowell H, Losty P, Barnes N, Kokai G. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer 2009;52:552.
14. Kleis M, Daldrup-Link H, Matthay K, Goldsby R, Lu Y, Schuster T et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging 2009;36:23-36.
15. Shore RM. Positron emission tomography/computed tomography (PET/CT) in children. Pediatr Ann 2008;37:404-12.
16. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008,190:1085-90.
17. Murphy JJ, Tawfeeq M, Chang B, Nadel H. Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. J Pediatr Surg 2008;43:2186-92.
18. Colavolpe C, Guedj E, Cammilleri S, Taieb D, Mundler O, Coze C. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer 2008;51:828-31.
19. Roca I, Simo M, Sábado C, de Toledo JS. PET/CT in paediatrics: it is time to increase its use! Eur J Nucl Med Mol Imaging 2007;34: 628-9.
20. Franzius C, Riemann B, Vormoor J, Kopka K, Wagner S, Rath B et al. Metastatic neuroblastoma demonstrated by whole-body PETCT using 11C-HED. Nuklearmedizin 2005;44:N4-5.
21. Parisi MT, Greene MK, Dykes TM, Moraldo TV, Sandler ED, Hattner RS. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol 1992;27:768-73.
22. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008;44:551-6.
23. Valk TW, Frager MS, Gross MD, Sisson JC, Wieland DM, Swanson DP et al. Spectrum of pheochromocytoma in multiple endocrine neoplasia. A scintigraphic portrayal using 1311-metaiodobenzylguanidine. Ann Intern Med 1981;94:762-7.
24. Wieland DM, Brown LE, Tobes MC, Rogers WL, Marsh DD, Mangner TJ et al. Imaging the primate adrenal medulla with [1231] and [1311] meta- iodobenzylguanidine: concise communication. J Nucl Med 1981;22:358-64.
25. Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine: pharmacology and clinical studies. Am J Physiol Imaging 1986;1: 96-103.
26. Guilloteau D, Chalon S, Baulieu JL, Huguet F, Desplanches G, Chambon C et al. Comparison of MIBG and monoamines uptake mechanisms: pharmacological animal and blood platelets studies. Eur J Nucl Med 1988;14:341-4.
27. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47.
28. Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37:286-302.
29. Wieland DM, Swanson DP, Brown LE, Beierwaltes WH. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med 1979;20:155-8.
30. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
31. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12-7.
32. Gelfand MJ. Meta-iodobenzylguanidine in children. Semin Nucl Med 1993;23:231-42.
33. Claudiani F, Stimamiglio P, Bertolazzi L, Cabria M, Conte M, Villavecchia GP et al. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma. Q J Nucl Med 1995;39(4 Suppl 1):21-4.
34. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC. Primary extra-adrenal pheochromocytoma: positive 1-123 MIBG imaging with negative 1-131 MIBG imaging. Clin Nucl Med 1986;11:851-4.
35. Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 2000;35:153-5.
36. Troncone L, Rufini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience. Eur J Nucl Med 1990;16:325-35.
37. Hadj-Djilani NL, Lebtahi NE, Delaloye AB, Laurini R, Beck D. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 1995;22:322-9.
38. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30:481-9.
39. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabeled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
40. Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J. Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990;31:129-34.
41. Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S et al. Integrated imaging using MRI and 1231 metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 2003;181:1115-24.
42. Geatti O, Shapiro B, Shulkin B, Hutchinson R, Sisson JC. Gastrointestinal iodine-131-meta-iodobenzylguanidine activity. Am J Physiol Imaging 1988;3:188-91.
43. Granata C, Carlini C, Conte M, Claudiani F, Campus R, Rizzo A. False positive MIBG scan due to accessory spleen. Med Pediatr Oncol 2001;37:138-9.
44. McGarvey CK, Applegate K, Lee ND, Sokol DK. False-positive metaiodobenzylguanidine scan for neuroblastoma in a child with opsoclonus-myoclonus syndrome treated with adrenocorticotropic hormone (acth). J Child Neurol 2006;21:606-10.
45. Moralidis E, Arsos G, Papakonstantinou E, Badouraki M, Koliouskas D, Karakatsanis C. 1231-Metaiodobenzylguanidine accumulation in a urinoma and cortex of an obstructed kidney after surgical resection of an abdominal neuroblastoma. Pediatr Radiol 2008;38:118-21.
46. Bahar RH, Mahmoud S, Ibrahim A, al-Gazzar AH. A false positive 1-131 MIBG due to dilated renal pelvis: a case report. Clin Nucl Med 1988;13:900-2.
47. Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C. Refining interpretation of MIBG scans in children. J Nucl Med 1994;35:803-10.
48. Pirson AS, Krug B, Tuerlinckx D, Lacrosse M, Luyx D, Borght TV. Additional value of 1-123 MIBG SPECT in neuroblastoma. Clin Nucl Med 2005;30:100-1.
49. Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B. lodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996;37:1464-8.
50. Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ. Iodine123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994;35:1753-7.
51. Shulkin BL, Shapiro B, Hutchinson RJ. Iodine-131-metaiodo-benzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med 1992;33:1735-40.
52. Daldnip-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jürgens H et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR AmJ Roentgenol 2001;177:229-36.
53. Mentzel HJ, Kentouche K, Sauner D, Fleischmann C, Vogt S, Gottschild D et al. Comparison of whole-body STIR-MRI and 99mTc-methylene-diphosphonate scintigraphy in children with suspected multifocal bone lesions. Eur Radiol 2004;14:2297-302.
54. Goo HW, Choi SH, Ghim T, Moon HN, Seo JJ. Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol 2005;35:766-73.
55. Lebtahi N, Gudinchet F, Nenadov-Beck M, Beck D, Bischof Delaloye A. Evaluating bone marrow metastasis of neuroblastoma with iodine-123-MIBG scintigraphy and MRI. J Nucl Med 1997;38:1389-92.
56. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397-405.
57. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy- D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-50.
58. Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M et al. Synthesis and preliminary evaluation of carbon-11-meta- hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med 1990;31:1328-34.
59. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996;37:16-21.
60. Schwaiger M, Hutchins GD, Kalff V, Rosenspire K, Haka MS, Mallette S et al. Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J Clin Invest 1991;87:1681-90.
61. Schwaiger M, Kalff V, Rosenspire K, Haka MS, Molina E, Hutchins GD et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 1990;82:457-64.
62. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992;33: 1125-31.
63. Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, VormoorJ etal. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med 2006;47: 1635-42.
64. Becherer A, Szabo M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 2004;45:1161-7.
65. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I et al. Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology 2002;222:507-12.
66. Mamede M, Carrasquillo JA, Chen CC, Del Corral P, Whatley M, Ilias I et al. Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)H-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 2006;27:31-6.
67. Valentiner U, Haane C, Peldschus K, Gustke H, Brenner W, Wilke F et al. [18F]FDG and [18F]RT PET-CT and MR imaging of human neuroblastomas in a SCID mouse xenograft model. Anticancer Res 2008;28(5A):2561-8.
68. Voss SD, Smith SV, DiBartolo N, Mcintosh LJ, Cyr EM, Bonab AA et al. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A 2007;104:17489-93.
69. Müller MF, Krestin GP, Willi UV. [Abdominal tumors in children. A comparison between magnetic resonance tomography (MRT) and ultrasonography (US)]. Rofo 1993;158:9-14.
70. Daldrup HE, Link TM, Wortler K, Reimer P, Rummeny EJ. MR imaging of thoracic tumors in pediatric patients. AJR Am J Roentgenol 1998; 170:1639-44.
71. Kaste SC. Issues specific to implementing PET-CT for pediatric oncology: what we have learned along the way. Pediatr Radiol 2004;34: 205-13.
72. Bar-Sever Z, Keidar Z, Ben-Barak A, Bar-Shalom R, Postovsky S, Guralnik L et al. The incremental value of 18F-FDG PET/CT in paediatric malignancies. Eur J Nucl Med Mol Imaging 2007;34: 630-7.
73. Olson PN, Everson LI, Griffiths HJ. Staging of musculoskeletal tumors. Radiol Clin North Am 1994;32:151-62.
74. Silberstein EB, Saenger EL, Tofe AJ, Alexander GW Jr, Park HM. Imaging of bone metastases with 99m Tc-Sn-EHDP (diphosphonate), 18 F, and skeletal radiography. A comparison of sensitivity. Radiology 1973;107:551-5.
75. Hahn K, Charron M, Shulkin BL. Role of MR imaging and iodine 123 MIBG scintigraphy in staging of pediatric neuroblastoma. Radiology 2003;227:908; author reply 08-9.
76. Shah Syed GM, Naseer H, Usmani GN, Cheema MA. Role of iodine-131 MIBG scanning in the management of paediatric patients with neuroblastoma. Med Princ Pract 2004;13:196-200.
77. Moon L, McHugh K. Advances in paediatric tumour imaging. Arch Dis Child 2005;90:608-11.
78. Nanni C, Rubello D, Castellucci P, Farsad M, Franchi R, Rampin L et al. 18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours. Biomed Pharmacother 2006;60:593-606.
79. Yeung HW, Schoder H, Smith A, Gonen M, Larson SM. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients. Mol Imaging Biol 2005;7:229-35.
80. Franzius C, Daldrup-Link HE, Sciuk J, Rummeny FJ, Bielack S, Jurgens H et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001;12:479-86.
81. Volker T, Denecke T, Steffen I, Misch D, Schonberger S, Plotkin M etat Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007;25:5435-41.
82. Gerth HU, Juergens KU, Dirksen U, Gerss J, Schober O, Franzius C. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med 2007;48:1932-9.